治疗选择有限的复杂肺部疾病患者。
complex pulmonary disease patients with limited treatment options.
作者信息
Aliberti Stefano, Blasi Francesco, Burgel Pierre-Régis, Calcagno Andrea, Fløe Andreas, Grogono Dorothy, Papavasileiou Apostolos, Polverino Eva, Prados Concepción, Rohde Gernot, Salzer Helmut J F, Sánchez-Montalvá Adrián, Shteinberg Michal, Van Braeckel Eva, van Ingen Jakko, Veziris Nicolas, Wagner Dirk, Loebinger Michael R
机构信息
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
IRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy.
出版信息
ERJ Open Res. 2024 Jan 15;10(1). doi: 10.1183/23120541.00610-2023. eCollection 2024 Jan.
相似文献
1
complex pulmonary disease patients with limited treatment options.
ERJ Open Res. 2024 Jan 15;10(1). doi: 10.1183/23120541.00610-2023. eCollection 2024 Jan.
2
Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
J La State Med Soc. 2008 Sep-Oct;160(5):248-54; quiz 254, 293.
3
Treatment of severe complex pulmonary disease with adjunctive amikacin and clofazimine standard regimen alone: a retrospective study.
ERJ Open Res. 2021 Nov 22;7(4). doi: 10.1183/23120541.00466-2021. eCollection 2021 Oct.
4
Long-Term Prognosis and Antimycobacterial Glycolipid Antibody as Biomarker in Mycobacterium avium-intracellulare Complex Pulmonary Disease.
Microbiol Spectr. 2022 Jun 29;10(3):e0053022. doi: 10.1128/spectrum.00530-22. Epub 2022 Apr 25.
5
Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease.
Respir Investig. 2022 Sep;60(5):613-624. doi: 10.1016/j.resinv.2022.05.006. Epub 2022 Jun 30.
6
Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease.
Microbiol Spectr. 2022 Aug 31;10(4):e0108822. doi: 10.1128/spectrum.01088-22. Epub 2022 Aug 11.
7
[Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
Kekkaku. 2013 Mar;88(3):355-71.
8
The Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease by Single Bacterial Isolation Plus Anti-GPL-Core IgA Antibody.
Microbiol Spectr. 2022 Feb 23;10(1):e0140621. doi: 10.1128/spectrum.01406-21. Epub 2022 Jan 5.
9
Characteristics of Circulating CD4 T Cell Subsets in Patients with Complex Pulmonary Disease.
J Clin Med. 2020 May 3;9(5):1331. doi: 10.3390/jcm9051331.
10
[Non-tuberculous mycobacteriosis. What has been coming out].
Kekkaku. 2011 Feb;86(2):113-25.
引用本文的文献
1
Clinicopathological characteristics and diagnostic performance of metagenomic pathogen detection technology in mycobacterial infections among HIV patients.
Front Cell Infect Microbiol. 2025 Apr 29;15:1584189. doi: 10.3389/fcimb.2025.1584189. eCollection 2025.
2
Clinical presentation and treatment outcomes of extrapulmonary nontuberculous mycobacterial infections with rapid and slow growth rates in Cali, Colombia.
BMC Infect Dis. 2025 Mar 31;25(1):444. doi: 10.1186/s12879-025-10681-4.
3
Growing from common ground: nontuberculous mycobacteria and bronchiectasis.
Eur Respir Rev. 2024 Jul 3;33(173). doi: 10.1183/16000617.0058-2024. Print 2024 Jul.
本文引用的文献
1
Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review.
Int J Infect Dis. 2022 Dec;125:120-131. doi: 10.1016/j.ijid.2022.10.013. Epub 2022 Oct 13.
2
Comparison of Rifamycins for Efficacy Against Complex and Resistance Emergence in the Hollow Fiber Model System.
Front Pharmacol. 2021 Apr 15;12:645264. doi: 10.3389/fphar.2021.645264. eCollection 2021.
3
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.
Eur Respir J. 2020 Jul 7;56(1). doi: 10.1183/13993003.00535-2020. Print 2020 Jul.
4
Real-life evaluation of clinical outcomes in patients undergoing treatment for non-tuberculous mycobacteria lung disease: A ten-year cohort study.
Respir Med. 2020 Apr;164:105899. doi: 10.1016/j.rmed.2020.105899. Epub 2020 Feb 14.
5
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study.
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
6
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.00170-2018. Print 2018 Mar.
7
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927.
8
Geographic Distribution of Nontuberculous Mycobacterial Species Identified among Clinical Isolates in the United States, 2009-2013.
Ann Am Thorac Soc. 2017 Nov;14(11):1655-1661. doi: 10.1513/AnnalsATS.201611-860OC.
9
Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis.
Clin Infect Dis. 2017 Oct 1;65(7):1077-1084. doi: 10.1093/cid/cix517.
10
Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases.
Ann Am Thorac Soc. 2016 Nov;13(11):1904-1911. doi: 10.1513/AnnalsATS.201604-246OC.
Zotero 插件